Dipòsit Digital de Documents de la UAB 18 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.02 segons. 
1.
9 p, 999.0 KB Long-Term Outcomes of Patients With Cocaine Use Disorder : A 18-years Addiction Cohort Study / Sanvisens, Arantza (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Hernandez-Rubio, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zuluaga Cruz, Andrea Paola (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Fuster, Daniel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Galan, Sara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Muga, Roberto (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Objective: Cocaine Use Disorder (CUD) has been associated with multiple complications and premature death. The purpose of the present study was to analyze the relationship between baseline medical comorbidity and long-term medical outcomes (i. [...]
2021 - 10.3389/fphar.2021.625610
Frontiers in Pharmacology, Vol. 12 (february 2021)  
2.
17 p, 1.4 MB Mephedrone and Alcohol Interactions in Humans / Papaseit Fontanet, Esther (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Pérez Mañá, Clara (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; de Sousa Fernandes Perna, Elizabeth B. (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; Olesti, Eulalia (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ; Mateus, Julian (Institut Hospital del Mar d'Investigacions Mèdiques) ; Kuypers, Kim PC (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; Theunissen, Eef L. (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; Fonseca Casals, Francina, 1972- (Institut Hospital del Mar d'Investigacions Mèdiques) ; Torrens, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ; Ramaekers, Jan G. (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; de la Torre, Rafael (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición) ; Farre, Magi (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Mephedrone (4-MMC, mephedrone) is a synthetic cathinone derivative included in the class of new psychoactive substances. It is commonly used simultaneously with alcohol (ethanol). The aim of the present study was to evaluate the interactions on subjective, cardiovascular and hormone effects and pharmacokinetics between mephedrone and alcohol in humans. [...]
2020 - 10.3389/fphar.2019.01588
Frontiers in Pharmacology, Vol. 10 (january 2020)  
3.
14 p, 7.7 MB Regulatory framework for advanced therapy medicinal products in Europe and United States / Iglesias-López, C. (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ; Obach, Mercè ; Vallano, A. (Servei Català de la Salut)
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The European Union (EU) and the United States (US) are fostering their development. For both regions, ATMPs fall under the regulatory framework of biological products, which determines the legal basis for their development. [...]
2019 - 10.3389/fphar.2019.00921
Frontiers in Pharmacology, Vol. 10 Núm. JULY (2019) , p. 921  
4.
9 p, 929.7 KB Reimbursement status and recommendations related to orphan drugs in European countries / Stawowczyk, E. (University of Bielsko-Biala. Faculty of Health Sciences) ; Malinowski, K.P. (Jagiellonian University Medical College) ; Kawalec, P. (Jagiellonian University Medical College) ; Bobiński, R. (Jagiellonian University Medical College) ; Siwiec, J. (Jagiellonian University Medical College) ; Panteli, D. (European Observatory on Health Systems and Policies) ; Eckhardt, H. (European Observatory on Health Systems and Policies) ; Simoens, S. (KU Leuven. Department of Pharmaceutical and Pharmacological Sciences) ; Agusti, A. (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Dooms, M. (University Hospitals Leuven) ; Pilc, A. (Polish Academy of Sciences. Institute of Pharmacology)
Objective: To review the reimbursement recommendations issued by selected European health technology assessment agencies for orphan drugs and the reimbursement status of these drugs; to assess the relationship between the type of recommendation and reimbursement status. [...]
2019 - 10.3389/fphar.2019.01279
Frontiers in Pharmacology, Vol. 10 (2019), p. 1279  
5.
8 p, 978.1 KB Soy isoflavone extract does not increase the intoxicating effects of acute alcohol ingestion in human volunteers / Martínez-Riera, R. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Pérez-Mañá, Clara (Institut Germans Trias i Pujol) ; Papaseit, Esther (Institut Germans Trias i Pujol) ; Fonseca, Francina (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; de la Torre, Rafael (Institut Hospital del Mar d'Investigacions Mèdiques) ; Pizarro Lozano, Nieves (Institut Hospital del Mar d'Investigacions Mèdiques) ; Torrens, Marta (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; Farre, Magi (Institut Germans Trias i Pujol)
Soy beans contain isoflavones, including daidzein and genistein, with biological activities related to therapeutic effects in reducing osteoporosis, decreasing adverse menopausal manifestations, providing protection from cardiovascular diseases, and reducing hormone-dependent cancers and age-related cognitive-decline. [...]
2019 - 10.3389/fphar.2019.00131
Frontiers in Pharmacology, Vol. 10 Núm. FEB (2019) , p. 131  
6.
25 p, 6.5 MB Impact of chronic risperidone use on behavior and survival of 3xTg-AD mice model of Alzheimer's disease and mice with normal aging / Torres-Lista, V. (Universitat Autònoma de Barcelona. Institut de Neurociències.) ; López-Pousa, S. (Institut d'Assistència Sanitaria. Research Unit and UVaMiD (Memory and Dementia Assessment Unit).) ; Giménez Llort, Lydia (Universitat Autònoma de Barcelona. Institut de Neurociències.)
Psychosis and/or aggression are common problems in dementia, and when severe or persistent, cause considerable patient distress and disability, caregiver stress, and early institutionalization. In 2005, the Food and Drug Administration (FDA) determined that atypical antipsychotics were associated with a significantly greater mortality risk compared to placebo, which prompted the addition of an FDA black-box warning. [...]
2019 - 10.3389/fphar.2019.01061
Frontiers in Pharmacology, Vol. 10 Núm. SEP (2019) , p. 1061  
7.
16 p, 2.7 MB Treatment with the delta opioid agonist UFP-512 alleviates chronic inflammatory and neuropathic pain : Mechanisms implicated / Polo, S. (Institut d'Investigació Biomèdica Sant Pau) ; Díaz, Andrés Felipe (Institut d'Investigació Biomèdica Sant Pau) ; Gallardo, Nuria (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Leánez, Sergi (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Balboni, G. (Department of Life and Environmental Sciences. Unit of Pharmaceutical. Pharmacological and Nutraceutical Sciences. University of Cagliari) ; Pol, Olga (Universitat Autònoma de Barcelona. Institut de Neurociències)
We investigated whether administration of the δ-opioid receptor (DOR) agonist H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), which also activates nuclear factor erythroid 2-related factor 2 (Nrf2), alleviated chronic inflammatory and/or neuropathic pain and inhibited the depressive-like behaviors associated with persistent neuropathic pain. [...]
2019 - 10.3389/fphar.2019.00283
Frontiers in Pharmacology, Vol. 10 Núm. MAR (2019) , p. 283  
8.
11 p, 2.0 MB Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients / Colom-Fernández, B. (Instituto de Investigación Hospital Universitario de la Princesa) ; Kreutzman, A. (Instituto de Investigación Hospital Universitario de la Princesa) ; Marcos-Jiménez, A. (Instituto de Investigación Hospital Universitario de la Princesa) ; García-Gutiérrez, V. (Hospital Universitario Ramón y Cajal (Madrid)) ; Cuesta-Mateos, C. (Instituto de Investigación Hospital Universitario de la Princesa) ; Portero-Sainz, I. (Instituto de Investigación Hospital Universitario de la Princesa) ; Pérez-García, Y. (Instituto de Investigación Hospital Universitario de la Princesa) ; Casado, L.F. (Servicio de Hematología y Hemoterapia. Hospital Virgen de la Salud) ; Sánchez-Guijo, F. (Servicio de Hematología y Hemoterapia. IBSAL-Hospital Universitario de Salamanca) ; Martínez-López, J. (Hospital 12 de Octubre (Madrid)) ; Ayala, R.M. (Hospital 12 de Octubre (Madrid)) ; Boqué, C. (Institut Català d'Oncologia) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Montero, I. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Soto, C. (Servicio de Hematología. Hospital Povisa) ; Paz, R. (Hospital Universitario La Paz (Madrid)) ; Silva, G. (Instituto de Investigación Hospital Universitario de la Princesa) ; Vega-Piris, L. (Instituto de Investigación Sanitaria Hospital Universitario de La Princesa) ; Steegmann, J.L. (Instituto de Investigación Hospital Universitario de la Princesa) ; Muñoz Calleja, Cecilia (Instituto de Investigación Hospital Universitario de la Princesa) ; Universitat Autònoma de Barcelona
Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. [...]
2019 - 10.3389/fphar.2019.01340
Frontiers in Pharmacology, Vol. 10 (2019) , p. 1340  
9.
19 p, 2.6 MB Propensity score methods in health technology assessment : Principles, extended applications, and recent advances / Ali, M.S. (Centre for Data and Knowledge Integration for Health (CIDACS). Instituto Gonçalo Muniz. Fundação Osvaldo Cruz) ; Prieto-Alhambra, Daniel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Lopes, L.C. (University of Sorocaba-UNISO) ; Ramos, D. (Centre for Data and Knowledge Integration for Health (CIDACS). Instituto Gonçalo Muniz. Fundação Osvaldo Cruz) ; Bispo, N. (Centre for Data and Knowledge Integration for Health (CIDACS). Instituto Gonçalo Muniz. Fundação Osvaldo Cruz) ; Ichihara, M.Y. (Institute of Public Health. Federal University of Bahia (UFBA)) ; Pescarini, J.M. (Centre for Data and Knowledge Integration for Health (CIDACS). Instituto Gonçalo Muniz. Fundação Osvaldo Cruz) ; Williamson, E. (Faculty of Epidemiology and Population Health. London School of Hygiene and Tropical Medicine) ; Fiaccone, R.L. (Department of Statistics. Federal University of Bahia (UFBA)) ; Barreto, M.L. (Institute of Public Health. Federal University of Bahia (UFBA)) ; Smeeth, L. (Centre for Data and Knowledge Integration for Health (CIDACS). Instituto Gonçalo Muniz. Fundação Osvaldo Cruz) ; Universitat Autònoma de Barcelona
Randomized clinical trials (RCT) are accepted as the gold-standard approaches to measure effects of intervention or treatment on outcomes. They are also the designs of choice for health technology assessment (HTA). [...]
2019 - 10.3389/fphar.2019.00973
Frontiers in Pharmacology, Vol. 10 (2019) , p. 973  
10.
17 p, 3.3 MB Evolutionary trends in RNA base selectivity within the RNase A superfamily / Prats-Ejarque, Guillem (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Lu, Lu (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Salazar, V.A. (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Moussaoui, Mohammed (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Boix i Borràs, Esther (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
There is a growing interest in the pharmaceutical industry to design novel tailored drugs for RNA targeting. The vertebrate-specific RNase A superfamily is nowadays one of the best characterized family of enzymes and comprises proteins involved in host defense with specific cytotoxic and immune-modulatory properties. [...]
2019 - 10.3389/fphar.2019.01170
Frontiers in Pharmacology, Vol. 10 (October 2019) , art. 1170  

Dipòsit Digital de Documents de la UAB : 18 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.